X-linked agammaglobulinemia overview

Revision as of 17:33, 21 September 2012 by Vishnu Vardhan Serla (talk | contribs) (Created page with "__NOTOC__ {{X-linked agammaglobulinemia}} {{CMG}} ==Overview== '''X-linked agammaglobulinemia''' (also called '''X-linked hypogammaglobulinemia,''' '''XLA''', '''Bruton type a...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

X-linked agammaglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating X-linked agammaglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Serology

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

X-linked agammaglobulinemia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of X-linked agammaglobulinemia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on X-linked agammaglobulinemia overview

CDC on X-linked agammaglobulinemia overview

X-linked agammaglobulinemia overview in the news

Blogs on X-linked agammaglobulinemia overview

Directions to Hospitals Treating X-linked agammaglobulinemia

Risk calculators and risk factors for X-linked agammaglobulinemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

X-linked agammaglobulinemia (also called X-linked hypogammaglobulinemia, XLA, Bruton type agammaglobulinemia) is a rare X-linked genetic disorder that affects the body's ability to fight infection (origin of the name: A=no, gammaglobulin=Antibody). XLA patients do not generate mature B cells. B cells are part of the immune system and normally manufacture antibodies (also called immunoglobulins) which defends the body from infections (the humoral response). Patients with untreated XLA are prone to develop serious and even fatal infections.[1] Patients typically present in early childhood with recurrent infections, particularly with extracellular, encapsulated bacteria.[2] XLA is an X-linked disorder, and therefore is almost always limited to males. It occurs in a frequency of about 1 in 100,000 male newborns, and has no ethnic predisposition. XLA is treated by infusion of human antibody. Treatment with pooled gamma globulin cannot restore a functional population of B cells, but it is sufficient to reduce the severity and number of infections due to the passive immunity granted by the exogenous antibodies.[2]

XLA is caused by a mutation on the X chromosome of a single gene identified in 1993 and known as Bruton's tyrosine kinase, or Btk.[2] XLA was first characterized by Dr. Ogden Bruton in a ground-breaking research paper published in 1952 describing a boy unable to develop immunities to common childhood diseases and infections. Bruton's paper describes the first known immune deficiency. XLA is classified with other inherited (genetic) defects of the immune system, known as primary immunodeficiency disorders.[3]

References

  1. XLA information by St. Jude Children's Hospital
  2. 2.0 2.1 2.2 X-Linked Agammaglobulinemia Patient and Family Handbook for The Primary Immune Diseases. Third Edition. 2001. Published by the Immune Deficiency Foundation
  3. Bruton, Ogden C. Agammaglobulinemia

Template:WH Template:WS